Texas GLP-1 Lawsuit Attorney
Diabetes and Weight Loss Drug Injury
The Texas GLP-1 lawsuit attorney team at Reich & Binstock has helped hundreds of clients across the country file lawsuits after suffering injuries and severe health issues after using Ozempic, Wegovy, Mounjaro, Trulicity, Saxenda, Rybelsus, or other weight loss medications. A growing number of lawsuits filed against Novo Nordisk and Eli Lilly allege that the manufacturers failed to warn diabetic and weight loss patients.
While manufacturers Novo Nordisk and Eli Lilly did warn of the minor side effects, they severely downplayed the increased risk of severe side effects and medical conditions.
While some GLP-1 medications received FDA approval for chronic weight management or promoting weight loss in the short term, most GLP-1 drugs, like Ozempic, Victoza, Basaglar, and Trulicity, were only FDA-approved for consumers with a type 2 diabetes diagnosis. This has resulted in many Ozempic lawsuits filed against Novo Nordisk and, in some individual cases, the doctors writing those prescriptions.
Pharmacies may also be responsible for negligently producing GLP-1 formulations that cause severe injuries or medical conditions. Because compounded semaglutide GLP-1 drugs aren’t subject to the same FDA approval process as brand-name GLP-1 receptor agonists, pharmacists have a heightened duty to ensure their formulations are correct.
Our Texas GLP-1 lawyers represent clients in filing weight loss drug lawsuits for all major pharmaceutical brands. If you were a patient taking Ozempic or another GLP-1 drug who was hospitalized or suffered from its severe side effects, a Texas GLP-1 attorney from our legal team can explain your legal options for recovery.
Contact a Texas GLP-1 lawsuit attorney from our law firm to schedule a free case evaluation by calling 713-622-7271 or using our online form.
We handle both individual cases and class action lawsuits on a contingency fee basis, so clients don’t owe anything unless the case is settled or we recover a jury award on your behalf.
Why Choose Our Texas GLP-1 Lawsuit Lawyer Team
Our Texas GLP-1 lawsuit lawyer team has a proven track record of success in mass tort litigation. We have decades of experience fighting major pharmaceutical companies like Novo Nordisk and Eli Lilly.
Our GLP-1 lawsuit attorneys in Texas help claimants across the nation in individual cases and class actions. We represent patients taking Ozempic, Wegovy, Mounjaro, Victoza, Saxenda, Rybelsus, and compounded semaglutide and tirzepatide. Many of our clients have experienced severe health issues after using this form of weight loss medication, which is often prescribed to treat obesity.
Many of the weight loss drug lawsuits allege that Novo Nordisk and Eli Lilly didn’t adequately warn consumers, despite having knowledge of the consistent, complex, and severe side effects. This was made worse by celebrity endorsements that didn’t disclose any severe injuries and side effects, only praising the GLP-1 drugs for their weight loss benefits.
The minor side effects of GLP-1 receptor agonists include:
- Nausea
- Vomiting
- Severe dehydration
- Diarrhea
- Constipation
- Abdominal pain
The severe side effects of GLP-1 drugs include:
- Pancreatitis
- Stomach paralysis (gastroparesis)
- Bowel obstruction
- Intestinal blockages
- Vision loss or damage to the optic nerve
- Gallbladder disease and gallstones
- Pulmonary embolism
- Kidney injury
- Maculopathy
- Hypoglycemia
- Biliary disease
- Diabetic retinopathy complications
- Increased risk of cancers and thyroid tumors
If you were diagnosed with severe health issues after taking glucagon-like peptide 1 weight loss drugs, like Ozempic, Wegovy, Mounjaro, Victoza, Saxenda, Rybelsus, or Trulicity, our Texas drug injury lawyers will help you file a GLP-1 lawsuit and fight to ensure you get the compensation you deserve.
Understanding GLP-1 Lawsuits in Texas
Our Texas GLP-1 lawsuits attorneys are filing in response to many clients alleging that the drug companies, Novo Nordisk and Eli Lilly, did not adequately warn consumers about the severe side effects. While they did indicate some minor side effects, the FDA may have never approved drugs like Ozempic if all the potential links were disclosed upfront.
The class of drugs that mimics glucagon-like peptide 1 (GLP-1) receptor agonists was developed to treat type 2 diabetes. Then, drug companies developed similar weight loss drugs to “treat obesity”, helping with chronic weight management and lowering blood sugar levels by stimulating insulin production and slowing digestion. After promoting weight loss benefits, the class of diabetes drugs belonging to GLP-1 receptor agonists, such as Ozempic, Victoza, Rybelsus, Basaglar, and Trulicity, started being prescribed to weight loss patients.
While there is off-label use, the GLP-1 weight loss lawsuits allege drug manufacturers Novo Nordisk and Eli Lilly’s failure to warn or even mention delayed gastric emptying on their labels. This slowed stomach has been tied to gastroparesis, bowel obstruction, and chronic vomiting.
Our Texas GLP-1 lawyers are helping clients across the U.S. file Ozempic lawsuits and other weight loss drug lawsuits against Eli Lilly and Novo Nordisk for putting profits over consumers’ health. We’re also pursuing lawsuits against third-party pharmacy compounders and manufacturers for delivering faulty formulations, and doctors prescribing diabetes drugs off-label when there are safer, FDA-approved weight loss medications.
Current GLP-1 Multidistrict Litigation Status
As of late 2025, there are 1,882 active cases in Multidistrict Litigation 3094, occurring in the Eastern District of Pennsylvania. Most weight loss drug lawsuits have allegations of gastroparesis, which affects the stomach’s gastric emptying processes. This is the focus of the multidistrict litigation 3094. Most cases target GLP-1 drugs like Ozempic, Wegovy, Mounjaro, and Trulicity, which contain active ingredients developed to treat type 2 diabetes and heart disease by regulating blood sugar levels.
Plaintiffs allege that the GLP-1 drug manufacturers, Eli Lilly and Novo Nordisk, failed to warn caused them harm. While the manufacturers did list minor side effects, the companies failed to mention delayed gastric emptying, nor were there adequate warnings for deep vein thrombosis, bowel obstruction, pulmonary embolism, or other health issues that required hospitalization in many cases.
The individual cases have been consolidated into multidistrict litigation in the district court.
If you want to join this Ozempic lawsuit or join the multidistrict litigation for other GLP-1 drugs like Wegovy, Mounjaro, Trulicity, Rybelsus, or others, contact a Texas GLP-1 lawsuit attorney from our law firm for a free case evaluation to explore your legal options.
Lawsuits Filed Against GLP-1 Manufacturers: Novo Nordisk and Eli Lilly and Company
Weight loss lawsuits brought against manufacturers, Eli Lilly and Novo Nordisk, allege that the drug companies failed to warn consumers, didn’t address design defects, and provided inadequate labeling for weight loss drugs like Ozempic, Wegovy, Mounjaro, Trulicity, and others. These weight loss drugs gained popularity shortly before widespread allegations of consumer fraud arose.
This means the active ingredient shouldn’t be consumed, even when manufactured as intended. Consumers also allege failure to warn about the significant risks of gastroparesis (stomach paralysis) and other serious gastrointestinal injuries. Our GLP-1 lawsuit attorney team provides skilled Texas product liability claims assistance, representing clients across the country who were diagnosed with serious health problems or have high medical expenses tied to GLP-1 weight loss medications.
Eli Lilly Lawsuit and GLP-1 Medications
Manufacturer Eli Lilly developed GLP-1 receptor agonists Mounjaro, Trulicity, and Zepbound. Mounjaro and Trulicity were approved as type 2 diabetes drugs. Eli Lilly then “developed” Zepbound. This is quite literally the same prescription as Mounjaro, only Zepbound is approved for chronic weight management.
Plaintiffs in litigation allege that Eli Lilly marketed the same drug under two brand names to capture separate consumers and insurance coverage.
The implications here are significant.
Eli Lilly reframed the diabetes prescription as a separate weight loss drug without enhancing its warning.
This strategy exposed more consumers, without diabetes or necessity, to the same undisclosed severe side effects, like gastrointestinal injuries and other complications. By promoting weight loss medications that weren’t developed for that, this effectively expanded market share, while Eli Lilly’s failure to warn of the permanent and debilitating side effects swept the nation.
If you were injured from being prescribed an Eli Lilly “weight loss” medication, contact a Texas GLP-1 lawsuits attorney at our law firm for a free case evaluation. We can represent you in seeking compensation.
Mounjaro Lawsuit
Our Texas GLP-1 lawyers are filing Mounjaro lawsuits against Eli Lilly and Company. Mounjaro is a glucagon-like peptide 1 (GLP-1) receptor agonist. This helps regulate blood sugar levels, slows gastric emptying, and promotes satiety, which results in off-label weight management. Mounjaro’s prescribing information includes warnings for thyroid c-cell tumors, pancreatitis, hypoglycemia, acute kidney injury, nausea, vomiting, diarrhea, and hypersensitive reactions, like anaphylaxis and angioedema.
However, Mounjaro GLP-1 lawsuits allege the following additional severe side effects:
- Gastroparesis (stomach paralysis)
- Bowel obstruction
- Gallbladder disease, gallstones, and cholecystitis
- Kidney failure
- Diabetic retinopathy complications
- Hypoglycemia (used with other diabetes medications)
- Vision loss
These severe side effects are a far cry from the mild side effects listed on the brand-name label. Our Texas Mounjaro attorneys are representing clients across the country who suffered gastroparesis or other gastrointestinal injuries because of Eli Lilly’s failure to warn about such dangers. If you want to pursue legal action, contact our law firm for a free case evaluation.
Trulicity Lawsuit
Our Texas GLP-1 lawyers are also pursuing Trulicity lawsuits. This Eli Lilly GLP-1 receptor agonist prescription was developed to manage type 2 diabetes. Trulicity’s warning label includes potential risks for thyroid c-cell tumors, pancreatitis, hypoglycemia, acute kidney injury, nausea, vomiting, diarrhea, hypersensitivity reactions, and diabetic retinopathy complications.
However, legal claims allege it carries more significant risks, a theme for Eli Lilly in these weight loss drug lawsuits. Severe side effects alleged in the Trulicity GLP-1 lawsuit include:
- Gastroparesis (stomach paralysis)
- Bowel obstruction
- Vomiting that’s chronic enough to cause major gastrointestinal issues
- Nausea well past the initial time frame
- Eye problems, like optic neuropathy and maculopathy
Our Texas Trulicity lawyers have extensive experience holding pharmaceutical companies liable for failure to warn about the debilitating outcomes of their GLP-1 medications.
GLP-1 Weight Loss Drugs Named in the Novo Nordisk Lawsuit
Our Texas GLP-1 injury lawyers are pursuing Ozempic lawsuits and other weight loss lawsuits against the manufacturer, Novo Nordisk, for its failure to warn about severe side effects.
Patients taking Ozempic, Wegovy, Rybelsus, Victoza, or Sazenda who suffered gastroparesis or other gastrointestinal injuries may be eligible to pursue a weight loss drug lawsuit against Novo Nordisk.
Contact a Texas GLP-1 lawsuit attorney from our legal team to determine if you qualify for an individual case or to join the ongoing litigation.
Ozempic Lawsuit
Ozempic received FDA approval to treat type 2 diabetes by regulating blood sugar levels. It’s also approved to reduce the risk of cardiovascular events, like heart attacks or strokes, for those with type 2 diabetes and a known heart disease. However, this diabetes drug has been widely prescribed off-label as a weight loss drug.
Novo Nordisk did disclose the risk of c-cell tumors, pancreatitis, hypoglycemia, acute kidney injury, nausea, vomiting, diarrhea, hypersensitivity reactions, and diabetic retinopathy complications. However, patients taking Ozempic have alleged other, more severe side effects related to the small intestine and large intestine, including:
- gastroparesis (stomach paralysis)
- bowel obstruction
- persistent vomiting leading to gastrointestinal damage
- ischemic optic neuropathy (NAION) vision loss
Plaintiffs argue that Novo Nordisk failed to provide adequate warnings about these dangers, leaving users unaware. Our Texas Ozempic lawyer group is actively reviewing Ozempic lawsuits and other claimants injured by other Novo Nordisk drugs like Ozempic.
Consult a Texas GLP-1 lawsuit attorney at our law firm to discuss a potential Ozempic lawsuit and settlement value.
Wegovy Lawsuit
Wegovy received FDA approval as a GLP-1 medication used for chronic weight management, namely to treat obesity or for those who are overweight and have high blood pressure, type 2 diabetes, or high cholesterol. Novo Nordisk did disclose information regarding thyroid c-cell tumors, pancreatitis, hypoglycemia, acute kidney injury, nausea, vomiting, diarrhea, hypersensitivity reactions, diabetic retinopathy complications, increased heart rate, and suicidal ideation.
However, many plaintiffs have alleged several undisclosed and more severe side effects for Wegovy, including:
- gastroparesis (stomach paralysis)
- bowel obstruction
- persistent vomiting leading to gastrointestinal injuries
- Chronic, treatment-resistant nausea well beyond the initial time permitted
- Vision loss
Our Texas GLP-1 lawyers are reviewing Wegovy lawsuits across the country. If you were prescribed Wegovy and suffered from one of the major conditions included in the Novo Nordisk failure to warn, you may be eligible to seek compensation. Consult a Texas Wegovy attorney to learn more.
Rybelsus Lawsuit
Rybelsus is FDA-approved for regulating blood sugar levels for those diagnosed with type 2 diabetes. Novo Nordisk did disclose risk of thyroid c-cell tumors, pancreatitis, hypoglycemia, acute kidney injury, nausea, vomiting, diarrhea, hypersensitivity reactions, and diabetic retinopathy complications.
However, plaintiffs allege that Novo Nordisk didn’t disclose severe side effects, including:
- gastroparesis
- bowel obstruction
- vomiting leading to gastrointestinal damage
- chronic, treatment-resistant nausea well beyond the initial time frame
- optic neuropathy and maculopathy
If you were diagnosed as a result of Novo Nordisk’s failure to warn, consult a Texas Rybelsus lawyer to see if you qualify for a GLP-1 drug lawsuit.
Victoza Lawsuit
The Victoza lawsuit focuses on legal claims that Novo Nordisk didn’t give adequate warnings for the GLP-1 receptor agonist. This was approved by the FDA for type 2 diabetes, not as a weight loss drug. Victoza does disclose the potential risk of thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), pancreatitis, hypoglycemia, kidney injury, gastrointestinal issues, hypersensitivity reactions, and retinopathy complications for those with diabetes.
Critics argue that these GLP-1 medications were marketed without sufficient disclosure, leaving patients with serious health complications and significant medical expenses. If you were harmed while taking Victoza for diabetes or if your prescription was used for weight loss benefits, consult a Texas Victoza lawsuit attorney to discuss your case.
Saxenda Lawsuit
Saxenda was FDA-approved to promote weight loss in adults with obesity, overweight adults with a weight-related medical condition, or patients with obesity over 12. This is a higher-dose version of liraglutide prescribed as a GLP‑1 receptor agonist for long-term weight loss. The Saxenda weight loss drug lawsuit alleges that Novo Nordisk didn’t adequately detail potential risks linked to Saxenda, including gastroparesis, bowel obstruction, chronic vomiting and dehydration, gastrointestinal damage, gallbladder disease and gallstones, and potentially blindness.
If you suffered any of the symptoms not named by Novo Nordisk, you may have a valid case. Discuss a potential weight loss drug lawsuit with a Texas Saxenda lawsuit attorney.
Other GLP-1 Receptor Agonist Brands, Compounded Semaglutide, and Off-Brand GLP-1 Drug Injury Cases Our Texas GLP-1 Attorney Team Handles
The Texas GLP-1 lawsuit lawyers on our legal team represent weight loss patients harmed by brand-name GLP-1 receptor agonists, like Ozempic, Wegovy, Mounjaro, Trulicity, Rybelsus, Victoza, and Saxenda. We also represent diabetic and weight loss patients injured by other weight loss drugs and GLP-1 medications, like Byetta, Bydureon, and Tanzeum, as well as pharmacy-created semaglutide and off-brand forms.
While marketed as effective weight loss medications, these drugs have been linked to serious complications such as intestinal blockages and permanent vision loss.
Many clients report ongoing symptoms ranging from gastrointestinal issues to vision problems that interfere with daily life. Our Texas GLP-1 attorney team works with healthcare providers and medical experts to investigate each case and fight for the compensation injured patients deserve.
Byetta and Bydureon Weight Loss Lawsuit Against AstraZeneca
Byetta and Bydureon were developed by Amylin Pharmaceuticals and Eli Lilly. Later, Bristol-Myers Squibb (BMS), then AstraZeneca, bought the rights. These were approved by the FDA to treat type 2 diabetes and manage blood sugar in adults with diabetes, not as a weight loss drug. Patients allege that AstraZeneca didn’t warn about pancreas swelling and inflammation, pancreatic cancer, thyroid cancer, and gastrointestinal issues.
These cases differ from the newer Ozempic, Wegovy, Mounjaro, and other GLP-1 drug lawsuits, but they raise similar concerns that GLP-1 drug makers didn’t disclose the more severe side effects, hindering doctors’ and patients’ ability to make informed decisions.
If you’ve been diagnosed with something new or have medical expenses caused by Byetta or Bydureon, call a Texas GLP-1 drug injury lawyer to discuss your case.
Compounded Semaglutide Lawsuit (Legal Claims Against Pharmacies)
FDA GLP-1 Shortage List Lawsuit
When demand for Ozempic, Wegovy, and other GLP-1 drugs skyrocketed, semaglutide was placed on the FDA’s Drug Shortages List. This allowed specific pharmacies to produce their own versions of the brand-name drugs. This created several problems:
Some compounders used semaglutide salts. These aren’t the same as the FDA-approved semaglutide base in Ozempic and Wegovy. Salt forms haven’t been evaluated for safety or effectiveness. Consumers allege these GLP-1 drugs are different from the approved drugs.
These pharmacy-created GLP-1 drugs aren’t subject to the same testing process. Some consumers allege they received GLP-1 medications that weren’t formulated correctly, contaminated, or didn’t follow their doctor’s dosing orders. Reports of hospitalizations followed.
Once the Novo Nordisk GLP-1 drug supply stabilized, pharmacies were expected to stop. However, some continued creating semaglutide forms anyway. Plaintiffs argue this violates federal statutes and exposes patients to unregulated semaglutide drugs.
Patients have pursued lawsuits alleging that they sustained serious harm from incorrect packaging, improper formulations, and a lack of safety warnings.
Unlicensed Pharmacy Operations
Because of the high demand for GLP-1 drugs, some clinics and online companies have prepared and sold compounded semaglutide without being licensed as a pharmacy or outsourcing facility. This means they bypassed testing requirements.
Additionally, some weight loss clinics and telehealth platforms shipped semaglutide injections across state lines without proper licensing.
We’ve also received reports of operations selling mislabeled semaglutide or counterfeit injections that contained the wrong active ingredient, concentration, or were contaminated.
Novo Nordisk has brought lawsuits, but consumers harmed by generic versions or contaminated forms of semaglutide can also pursue a diabetes or weight loss drug lawsuit. If you’ve suffered severe harm from GLP-1 drugs that weren’t manufactured correctly, such as intestinal damage, hospitalization, or significant medical expenses, call a Texas GLP-1 lawyer to discuss your claim.
We provide skilled Houston medical malpractice claims assistance for clients harmed by unsafe semaglutide. Our Texas GLP-1 lawyer team conducts thorough investigations and works with healthcare providers and medical experts to build strong cases to help plaintiffs secure compensation for medical expenses and injury treatment.
Lawsuits for Research Peptides GLP-1 Products
Research-grade GLP-1 peptide products are formulations marketed for laboratory use but illegally sold direct-to-consumer for personal use. This is because the GLP-1 drugs don’t undergo the same testing and regulatory processes as FDA-approved GLP-1 medications. Such weight loss drugs can be marketed under their brand name or a generic version, but they are not approved, tested, or labeled as safe for human use.
Plaintiffs allege that research GLP-1 drugs were sold for weight loss despite disclaimers and that consumers sustained injuries such as gastroparesis, intestinal obstruction, pancreatic damage, kidney damage, and more.
The medical community has raised concerns about dangerous dosing, purity issues, and the fact that these substances are essentially unregulated, with limited safety or efficacy data.
Many weight loss lawsuits now involve cases where consumers found they were misled by illegal marketing and were unable to make fully informed decisions about the risks involved.
GLP-1 Online Distributor Lawsuits
Texas GLP-1 online distributor lawsuits involve legal actions against individuals or companies engaged in bootleg weight loss drug sales without being approved for doing so.
These cases often stem from consumer protection violations, unauthorized medical practice claims, and the illegal sale of GLP-1 medications marketed to promote weight loss. Some companies misrepresent themselves as legitimate prescribers or use misleading marketing to sell contaminated, counterfeit, or improperly dosed weight loss drugs.
Online GLP-1 online distributor lawsuits involve fraudulent drug makers who sold weight loss drugs through unauthorized channels. The legal claims focus on the harm to consumers who believed they were buying approved GLP-1 drugs for obesity or diabetes.
Increased Risks and Side Effects of GLP-1 Weight Loss Medications
While GLP-1 weight loss medications have shown positive results in clinical trials, they have also been linked to a range of serious and minor side effects. Many patients experienced severe injuries, like bowel obstruction, ileus (intestinal paralysis), pulmonary embolism, vision loss, gallstones, severe dehydration, and intense abdominal pain, many of which have required hospitalization.
Patients have also experienced vomiting, diarrhea, and bloating, which can progress from manageable discomfort to significant health concerns if untreated.
Ongoing research continues to examine the long-term safety of these medications. Our experienced Texas GLP-1 lawyer group is reviewing claims and helping clients determine the best course of legal action.
Gastroparesis and Stomach Paralysis
Gastroparesis, also known as stomach paralysis, is a serious digestive condition characterized by delayed gastric emptying, where the stomach muscles fail to move food efficiently into the colon. This complication has been reported by victims taking GLP-1 medications such as Wegovy, Mounjaro, and Ozempic, leading to persistent vomiting and, in some cases, malnutrition. Gastroparesis can cause permanent digestive issues that may never resolve. Early diagnosis and treatment for gastroparesis are essential to preserve overall health.
Patients with gastroparesis experience severe disruptions to daily life related to reduced muscle function in the digestive tract. New cases are being filed increasingly more over time. Our Texas GLP-1 lawsuit lawyers are reviewing gastroparesis cases now.
NAION and Vision Loss Complications
Non-arteritic anterior ischemic optic neuropathy (NAION) is a rare eye condition that occurs when blood flow to the optic nerve is suddenly reduced, potentially causing sudden vision loss that may never resolve. NAION cases have been reported in patients taking GLP-1 medications, like Wegovy, Mounjaro, Ozempic, Rybelsus, and Zepbound. The World Health Organization (WHO) notes that risk factors can include certain medical conditions and changes in blood glucose levels that may affect the optic nerve blood supply.
The Food and Drug Administration (FDA) acknowledges this but continues to provide inadequate warning labels that don’t highlight NAION as a potential risk. This has led to concerns that doctors and patients can’t make informed decisions before starting treatment or writing prescriptions.
Intestinal Obstruction and Blockages
FAERS collects reports from doctors, patients, and manufacturers about health problems that occur after taking a drug. In September 2024, the FDA required updated warning labels for Wegovy, Mounjaro, and Ozempic for intestinal obstruction (ileus) after numerous cases of intestinal obstruction (ileus) in patients using GLP-1 receptor agonists were reported. These blockages included ileus, small intestine blockage (bowel), large intestine blockage (colon obstruction), partial obstruction, complete obstruction, and secondary complications, like bowel ischemia and perforation.
Reported symptoms include abdominal pain, persistent vomiting, diarrhea, and severe dehydration. While clinical testing confirms these GLP-1 receptor agonists can deliver substantial weight loss results, post-market data show that intestinal blockages are a rare but dangerous risk.
If you were diagnosed with obstruction of the small intestine or large intestine, required surgery or hospitalization, call a Texas GLP-1 attorney to discuss your case.
How to Join the GLP-1 Class Action Lawsuit in Texas
If you or a loved one has suffered serious side effects after taking a GLP-1 medication, you may be eligible to participate in a class action for the diabetes or weight loss drug. Joining class actions means that a Texas GLP-1 attorney will review your symptoms, collect your medical records, and use this evidence to build a weight loss drug lawsuit to secure compensation on your behalf.
Based on your medical records and class action guidelines, we can determine your eligibility and position your case for success. We handle diabetes medication and weight loss drug lawsuits to help clients maximize recovery and seek justice.
Who Can Join the GLP-1 Lawsuit in Texas?
You may be eligible to join the GLP-1 lawsuit in Texas if you have suffered severe health complications or adverse effects after taking a weight loss drug such as Ozempic, Wegovy, Mounjaro, or another GLP-1 medication. This includes consumers who required hospitalization, needed ongoing medical treatment, or experienced lost income due to their injuries.
Our Texas GLP-1 attorneys can review your case, determine if your condition is linked to a GLP-1 drug, and guide you through the legal process to pursue the justice and compensation you deserve.
Statute of Limitations for GLP-1 Claims
Product liability/drug injury claims: Texas consumers must file product liability and drug injury claims involving GLP-1 medications within two years from the date the injury occurred or should have reasonably been discovered.
This time applies to those who have suffered severe harm or adverse effects from a GLP-1 diabetes or weight loss drug, such as Ozempic, Wegovy, Mounjaro, or other GLP-1 receptor agonist. If you’ve sustained injuries from GLP-1 drugs, contact our Texas product liability lawyers.
Wrongful death claims: GLP-1 drug wrongful death claims are subject to a two-year filing period, beginning on the date the individual passes. Eligible family members can file wrongful death claims when a loved one’s death is caused by or linked to GLP-1 medications.
Our Texas wrongful death attorney and drug injury lawyers can collect medical records and other evidence. Early legal intervention allows time to secure vital evidence and build strong cases before the deadline passes.
Contact a Texas GLP-1 Lawyer For a Free Consultation
If you were diagnosed with a condition or suffered complications from taking a GLP-1 medication, our dedicated Texas GLP-1 attorneys from our legal team can help. We understand how diabetes drugs and weight loss drugs affect your body and overall health care needs.
In many cases, injured patients may qualify to pursue compensation for medical expenses, future treatment costs, lost income, and other damages. You don’t pay anything unless we win your case.
To find out if you qualify and get answers about your potential claim, call 713-622-7271 or contact us online to schedule your free consultation with a Texas GLP-1 lawyer.
There is never a fee unless we recover on your behalf.
Additionally, clients are not obligated to pay expenses if a recovery is not made.
